{"nctId":"NCT04492020","briefTitle":"Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants","startDateStruct":{"date":"2020-08-21","type":"ACTUAL"},"conditions":["Migraine"],"count":518,"armGroups":[{"label":"Treatment Sequence A","type":"EXPERIMENTAL","interventionNames":["Drug: Ubrogepant 100 mg","Drug: Placebo"]},{"label":"Treatment Sequence B","type":"EXPERIMENTAL","interventionNames":["Drug: Ubrogepant 100 mg","Drug: Placebo"]}],"interventions":[{"name":"Ubrogepant 100 mg","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* At least a 1-year history of migraine with or without aura consistent with a diagnosis according to the ICHD-3 (International Classification of Headache Disorders 3rd edition)\n* Migraine onset before age 50 years\n* By history, the participant's migraines typically last between 4 and 72 hours if untreated or treated unsuccessfully and migraine episodes are separated by at least 48 hours of headache pain freedom\n* History of 2 to 8 migraine attacks per month with moderate to severe headache in each of the 3 months prior to the Screening Visit\n\nExclusion Criteria:\n\n* Difficulty distinguishing migraine headache from tension-type or other headaches\n* Participants who overuse medication for migraine defined as use of opioids or barbiturates \\> 2 days/month, triptans or ergots ≥ 10 days/month, or simple analgesics (eg, aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen) ≥ 15 days/month in the 3 months prior to Visit 1 per investigator's judgment\n* Has a history of migraine aura with diplopia or impairment of level of consciousness, hemiplegic migraine, or retinal migraine as defined by ICHD-3\n* A current diagnosis of chronic migraine as defined by ICHD-3 or a history of 15 or more headache days per month on average in the 6 months prior to Visit 1 in the investigator's judgment. A headache day is defined as a day in which there was any occurrence of a headache of a minimum duration of 2 hours or a headache of any duration for which acute medication was taken\n* Has a current diagnosis of new persistent daily headache, trigeminal autonomic cephalgia (eg, cluster headache), or painful cranial neuropathy as defined by ICHD-3\n* Required hospital treatment of a migraine attack 3 or more times in the 6 months prior to Visit 1\n* History of malignancy in the 5 years prior to Visit 1, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer\n* History of any prior gastrointestinal conditions (eg, diarrhea syndromes, inflammatory bowel disease) that, per investigator judgment, may affect the absorption or metabolism of the study intervention; participants with prior gastric bariatric interventions (eg, Lap Band) which have been reversed are not excluded","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Reporting Absence of Headache of Moderate/Severe Intensity Within 24 Hours Post-dose","description":"The absence of a headache of moderate/severe intensity will be recorded by the participant in an electronic diary (eDiary) within 24 hours after taking double-blind study intervention during the prodrome in order to determine the attenuation of headache. The absence of moderate or severe headache are derived based on headache record and rescue use.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"121","spread":null},{"groupId":"OG001","value":"190","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Reporting Absence of Headache of Moderate or Severe Intensity Within 48 Hours Post-dose","description":"The absence of a headache of moderate or severe intensity will be recorded by the participant in an eDiary within 48 hours after taking double-blind study intervention during the prodrome in order to determine the prevention of headache","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"159","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Reporting Improvement in the Ability to Function Normally Over 24 Hours Post-dose","description":"The Functional Disability Scale (FDS) is a single item used to measure the participant's level to function normally. Participants will be asked to rate the performance of daily activities using 4 response options ranging from 0 (no disability, able to function normally) to 3 (severely impaired, cannot do all or most things, bed rest may be necessary) within 24 hours after taking double-blind study intervention during the prodrome","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null},{"groupId":"OG001","value":"107","spread":null}]},{"measurements":[{"groupId":"OG000","value":"336","spread":null},{"groupId":"OG001","value":"311","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"110","spread":null},{"groupId":"OG001","value":"156","spread":null}]},{"measurements":[{"groupId":"OG000","value":"311","spread":null},{"groupId":"OG001","value":"266","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"150","spread":null},{"groupId":"OG001","value":"199","spread":null}]},{"measurements":[{"groupId":"OG000","value":"269","spread":null},{"groupId":"OG001","value":"213","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"173","spread":null},{"groupId":"OG001","value":"245","spread":null}]},{"measurements":[{"groupId":"OG000","value":"244","spread":null},{"groupId":"OG001","value":"170","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"210","spread":null},{"groupId":"OG001","value":"266","spread":null}]},{"measurements":[{"groupId":"OG000","value":"190","spread":null},{"groupId":"OG001","value":"129","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"239","spread":null},{"groupId":"OG001","value":"291","spread":null}]},{"measurements":[{"groupId":"OG000","value":"155","spread":null},{"groupId":"OG001","value":"97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"342","spread":null},{"groupId":"OG001","value":"367","spread":null}]},{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"46","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Reporting Absence of Headache of Any Intensity Within 24 Hours Post-dose","description":"The absence of a headache of moderate/severe intensity will be recorded by the participant in an electronic diary (eDiary) within 24 hours after taking double-blind study intervention during the prodrome in order to determine the attenuation of headache. The absence of moderate or severe headache are derived based on headache record and rescue use.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"103","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":462},"commonTop":["NAUSEA","DIZZINESS","FATIGUE","SOMNOLENCE"]}}}